BioPhorum

BioPhorum

Membership-based forums for biopharma and devices

Overview

BioPhorum is a B2B membership organization that enables collaboration across global biopharmaceutical and medical device industries. It provides a non-competitive space where leaders and experts tackle shared challenges, define best practices, and advance projects through focused forums called Phorums. Members from license holders, manufacturers, CDMOs, and suppliers work on industry-wide initiatives to improve operations, reduce costs, and streamline regulatory processes, plus tools like the Digital Plant Maturity Model (DPMM) to guide digital transformation. Its goal is to accelerate progress in biopharma and medical device manufacturing by sharing knowledge, setting industry-wide practices, and improving efficiency and regulatory readiness.

Significant Headcount Growth

About BioPhorum

Simplify's Rating
Why BioPhorum is rated
B-
Rated B on Competitive Edge
Rated B on Growth Potential
Rated C on Differentiation

Industries

Data & Analytics

Consulting

Industrial & Manufacturing

Biotechnology

Company Size

51-200

Company Stage

N/A

Total Funding

N/A

Headquarters

London, United Kingdom

Founded

2008

Get referred to BioPhorum

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • February 2026 advisory board signals stronger C-suite pull from Pfizer, Sanofi, and Merck.
  • June 2026 PharmaX acquisition expands digital solutions beyond meetings into operational consulting.
  • July 2026 Host Cell Protein Data Platform relaunch creates recurring, data-driven product revenue.

What critics are saying

  • BioPhorum now integrates four acquisitions since 2024, creating execution risk through 2026.
  • Membership subscriptions drive revenue; Pharma budget tightening at big pharma can hit renewals fast.
  • Competitors can copy forum content; without member engagement, BioPhorum becomes a commodity network.

What makes BioPhorum unique

  • BioPhorum’s 2008 Phorums convene Pfizer, GSK, and Lilly on shared manufacturing problems.
  • The 2026 Strategic Advisory Board adds 14 senior executives, deepening member credibility and access.
  • BioPhorum turned collaboration into products through Brookwood, Inspired Pharma, and PharmaX acquisitions.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible Work Hours

Growth & Insights and Company News

Headcount

6 month growth

5%

1 year growth

5%

2 year growth

5%
BioProcess International
Aug 31st, 2026
eBook: technology transfer - minding the gaps amid digital transformation.

eBook: technology transfer - minding the gaps amid digital transformation. August 31, 2026 Download pdfdownload Sponsored by Avid Bioservices, Fujifilm Biotechnologies, IDBS, Lifecore, Lonza, Stellix, and Valgenesis Whether across two company sites or from a drug developer to a contract manufacturer, successful technology transfer hinges upon careful assessment of potential gaps in facility fit and process execution. Considering the proliferation of digital platforms for batch records, regulatory documentation, process monitoring, and many other biomanufacturing activities, the articles in this eBook explore ways to "mind the gap" during technology transfer, especially where it concerns transfer of critical process and product knowledge. First, a biotech journalist reports on progress achieved by the BioPhorum Technology Strategy team, which, based on the iconic London Underground map, has been developing an interactive "technology maturity matrix" to help biomanufacturers plot out their journeys from manual operations to "fully lights-out facilities," including even digitalized, automated technology transfers. The writer explores how companies moving through the matrix's steps might reap measurable improvements in cost, speed, quality, and agility. Next, BPI's news editor and managing editor reflect on a memorable BPI West presentation by industry consultant Laura Buttafoco (Protea). Pointing to industry examples, Buttafoco emphasized the need for complete information-sharing during transfers and gave examples showing what can go wrong when receiving sites do not receive complete information from batch records and other required documentation. Finally, an independent program execution leader makes the case for incorporating vendor-governance activities into companies' quality systems. Vendor governance, he explains, is often discussed as a matter of performance management or partnership health. But such conceptions underestimate how the work performed by vendors and external partners during technology transfer and outsourced manufacturing support regulatory decisions. The writer highlights five controls that can help quality teams to facilitate governance work. Download the eBook to learn about ways to facilitate technology transfer in a rapidly digitalizing biopharmaceutical industry. Download pdfdownload Sep 22, 2026 TO Sep 25, 2026 The leading bioprocessing event in Boston: 3,000+ bioprocessing professionals converge for expert insights in cell culture and upstream processing, cell line development, downstream bioprocessing, CMC innovation, and biologics scale-up strategies amongst other content streams. The exhibition side showcases the latest in biomanufacturing technologies, with the event providing ample networking opportunities with industry peers in bioprocessing and cell line development at BioProcess International (BPI), part of Biotech Week Boston. Join our 70,000+ readers. And yes, it's completely free. Custom reports. Sponsored Content Aug 28, 2026 eBooks. Sponsored Content Aug 31, 2026 Sponsored Content Aug 24, 2026 Innovative technology. Sponsored Content Sep 1, 2026 Sponsored Content Jul 28, 2026 Sponsored Content Jul 27, 2026 Webinars. Sponsored Content

PR Newswire
May 7th, 2026
BioPhorum Acquires PharmaX Solutions, Empowering The Life Sciences Industry to Turn Best Practice Insight into Operational Solutions at Scale

/PRNewswire/ -- BioPhorum has acquired PharmaX Solutions, a consultancy specialising in digital transformation and end-to-end digital manufacturing solutions...

PR Newswire
Feb 5th, 2026
BioPhorum forms Strategic Advisory Board with 14 pharma executives to accelerate industry collaboration

BioPhorum, a pharmaceutical industry collaborative network, has announced the formation of its inaugural Strategic Advisory Board comprising 14 senior executives from major pharmaceutical companies. The board will provide executive guidance on critical industry challenges including global regulation, new technology and supply chain resilience. Members include executives from Pfizer, GSK, Eli Lilly, Amgen, Sanofi, Merck, SK Pharmteco, Fujifilm BioTechnologies, eXmoor, Sartorius, UCB and Cytiva. The board will serve as a forum for strategic dialogue on pressing industry-wide challenges and opportunities. BioPhorum CEO Deborah Kobewka described the board's launch as "a defining milestone", noting that executive-led direction is crucial as the industry navigates volatility and a challenging global investment landscape. The board aims to help members turn market complexity into a shared roadmap for sustainable growth.

PharmiWeb
Dec 18th, 2025
BioPhorum acquires Inspired Pharma to enhance its training and support for pharmaceutical professionals worldwide

Media Release 17 December 2025 BioPhorum acquires Inspired Pharma to enhance its training and support for pharmaceutical professionals worldwide Strategic acquisition strengthens BioPhorum’s ability to deliver insight, expertise, and practical solutions to its global membership and life sciences client community across the pharmaceutical value chain BioPhorum is pleased to announce the acquisition of Inspired Pharma, a leading provider of specialist training for the...

PharmiWeb
May 20th, 2025
Biophorum Announces Appointment Of Dr. Uwe Buecheler To Board Of Directors

19 May 2025London, UKBioPhorum, the global organisation accelerating collaboration between biopharmaceutical and medical device industry leaders, is pleased to announce the appointment of Dr. Uwe Buecheler, as Non-Executive Director (NED) to its Board of Directors, effective May 19, 2025.Dr. Buecheler brings a wealth of experience and expertise in the biopharmaceutical industry, having held various leadership roles in development operations, strategic planning, and innovation. He has overseen more than 30 biologics launches, including several top global biopharmaceuticals and has held senior roles in regulatory affairs, CMC development, biosafety, quality, CDMO business and operations.Dr. Buecheler led the expansion of Boehringer Ingelheim's Global Operations Network in the US and China and pioneered the first Biologics MAH approval in Shanghai. He also contributed to major expansion projects in aseptic processing, microbial manufacturing, and large-scale mammalian cell culture operations

Recently Posted Jobs

Sign up to get curated job recommendations

BioPhorum is Hiring for 6 Jobs on Simplify!

Find jobs on Simplify and start your career today

Don't see your dream role? Check out thousands of other roles on Simplify. Browse all jobs →